Q-omics provides the consensus-scored ADM5 profile across patient tissues and cancer cell-line models. ADM5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ADM5 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, ADM5 RNA expression shows 13,953 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where ADM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADM5 survival associations across molecular data types. ADM5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADM5 RNA expression–survival associations across cancer types. High ADM5 expression shows unfavorable associations in KIRC, ACC, COAD, KIRP, MESO and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ADM5 RNA expression.
This table summarizes ADM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ADM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADM5 shows lower tumor expression in LUAD, KICH and BRCA and higher tumor expression in COAD, ESCA and CHOL. The LUAD box plot shows higher ADM5 RNA expression in normal versus tumor tissue (log2 FC = −0.987, t-test p < 0.001).
This table shows molecular features associated with ADM5 in patient tissues and cancer cell lines. In patient samples, ADM5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ADM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
